title: Consensus statement on the safety profile of topical calcineurin inhibitors.
authors.forename: T
authors.initials: T
authors.lastname: Bieber
authors.forename: M
authors.initials: M
authors.lastname: Cork
authors.forename: C
authors.initials: C
authors.lastname: Ellis
authors.forename: G
authors.initials: G
authors.lastname: Girolomoni
authors.forename: R
authors.initials: R
authors.lastname: Groves
authors.forename: R
authors.initials: R
authors.lastname: Langley
authors.forename: T
authors.initials: T
authors.lastname: Luger
authors.forename: M
authors.initials: M
authors.lastname: Meurer
authors.forename: D
authors.initials: D
authors.lastname: Murrell
authors.forename: S
authors.initials: S
authors.lastname: Orlow
authors.forename: A
authors.initials: A
authors.lastname: Paller
authors.forename: Y
authors.initials: Y
authors.lastname: de Prost
authors.forename: L
authors.initials: L
authors.lastname: Puig
authors.forename: J
authors.initials: J
authors.lastname: Ring
authors.forename: J-H
authors.initials: JH
authors.lastname: Saurat
authors.forename: T
authors.initials: T
authors.lastname: Schwarz
authors.forename: N
authors.initials: N
authors.lastname: Shear
authors.forename: G
authors.initials: G
authors.lastname: Stingl
authors.forename: A
authors.initials: A
authors.lastname: Taieb
authors.forename: K
authors.initials: K
authors.lastname: Thestrup-Pedersen
mesh_terms: D000287:Administration, Topical; D065095:Calcineurin Inhibitors; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D003876:Dermatitis, Atopic / Q000175:diagnosis / Q000188:drug therapy*; D064420:Drug-Related Side Effects and Adverse Reactions; D006801:Humans; D018570:Risk Assessment; D016559:Tacrolimus / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D065095:Calcineurin Inhibitors; C117268:pimecrolimus; D016559:Tacrolimus